HOME > TOP STORIES

TOP STORIES

BUSINESS Pfizer Japan Resolved to Drive Vaccine Demand, New Drug Launches: President

January 30, 2025
REGULATORY Pfizer’s Litfulo Braced for Price Cut after Cost-Effectiveness Assessment

January 30, 2025
REGULATORY MHLW Panel Finalizes NIP Inclusion of Shingles Jabs, OKs New Basic Immunization Plan

January 30, 2025
BUSINESS Nichi-Iko to Start Production Collaboration with Kyowa in FY2025: President

January 29, 2025
REGULATORY LDP-OK’ed Bill for PMD Act Amendment Specifies Launch of Innovative Drug Fund

January 28, 2025
BUSINESS Sanofi Stages V-Shaped Recovery in Vaccine Biz, Set for Growth with New Products Beyond Hib

January 27, 2025
BUSINESS MHLW Planning 10-Year Fund for Drug Discovery, Official Reveals at JPMA Meeting

January 24, 2025
REGULATORY MHLW Eyes 2 Biz Models as It Pushes Generic Industry Shakeup: Minister

January 23, 2025
BUSINESS Sanofi CEO Warns Off-Cycle Price Cuts Will Dilute Attractiveness of Japan Market

January 22, 2025
REGULATORY Astellas’ Xtandi on 2nd Drug List Up for IRA Price Negotiations

January 21, 2025
BUSINESS Nxera’s 50 Billion Yen Global Sales Goal “Conservative Figure”: Japan Chief

January 20, 2025
BUSINESS Industry Appreciates Raise in Minimum NHI Prices, but See It as Mere Drop in Bucket

January 17, 2025
REGULATORY 3 JAK Inhibitors, Wegovy and More Drugs Enjoy First Off-Year Application of Post-Launch Premiums

January 16, 2025
REGULATORY Govt Must Not Let Pro-Innovation Reform of 2024 Go to Waste: Sr Vice Minister

January 15, 2025
BUSINESS SGLT2 Inhibitor Forxiga Braced for Generic Entry in 2025

January 14, 2025
BUSINESS Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential

January 10, 2025
COMMENTARY Japan Expects to Approve/List 43 Novel Drugs in 2025 Including Ultra-Expensive Gene Therapies

January 9, 2025
ORGANIZATION Pharma CEOs Discouraged by Off-Year Revision, but Give Certain Credit to Category-Based Scope

January 9, 2025
REGULATORY MHLW Official Reveals Rationales Behind Off-Year Decision, Says PMP Return Is Reasonable

January 8, 2025
BUSINESS Daiichi Sankyo to Transfer Avastin Biosimilar to Amgen in Japan

January 8, 2025

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Shift Underway in Pharma Workforce as Sales Roles Shrink, Manufacturing Rises

By Hayate Horiguchi

Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…